Clinical Trial Update: Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial assessing safety and efficacy of BFB-101, an AAV9-delivered AP4B1 gene therapy, for AP4B1-related Hereditary Spastic Paraplegia Type 47…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Spastic Paraplegia
• Hereditary Spastic Paraplegia Type 47

Drugs mentioned

• BFB-101 (AAV9-AP4B1 gene therapy)

Snippet

Sponsor: BlackfinBio Ltd | Conditions: HSP, Hereditary Spastic Paraplegia | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING